Fig. 6
From: NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer
Representative cresyl-violet stained brain sections from a vehicle, (b) irinotecan, (c) NKTR-102 10 mg/kg, and (d) NKTR-102 50 mg/kg treated animals. Tumor regions are outlined and shaded. (e) The number of detectable brain metastases by treatment. Significant differences (p < 0.05 and p < 0.01) were observed in the number of CNS metastases in animals treated with low dose (9.2 ± 1.7) and high dose NKTR-102 (0.54 ± 0.2) compared to vehicle (16.4 ± 1.4) and irinotecan (14.5 ± 1.6) treated animals. (f) The average size of the CNS metastasis (μm2) was smaller in animals treated with low dose (0.17 ± 0.02) and high dose NKTR-102 (0.04 ± 0.01) compared to vehicle (0.29 ± 0.3) and irinotecan (0.26 ± 0.2) treated animals. All data are Mean ± SEM (n = 5-10)